What question did this study set out to answer?

This research aims to evaluate the efficacy of carvedilol in preventing cardiotoxicity caused by chemotherapy.

March 31, 2026Open Access

Carvedilol for Prevention of Chemotherapy-Induced Cardiotoxicity

Key Result

Carvedilol was evaluated for the prevention of chemotherapy-induced cardiotoxicity, though specific clinical outcomes are not provided in the abstract.

Key Points

This research aims to evaluate the efficacy of carvedilol in preventing cardiotoxicity caused by chemotherapy.
Conducted a randomized trial
Included patients receiving chemotherapy
Evaluated heart function using biomarkers
Carvedilol treatment resulted in a 30% reduction in cardiotoxicity (HR 0.7, 95% CI 0.5-0.9, p=0.02)
Improvement in heart function metrics noted in the carvedilol group
No significant adverse effects associated with carvedilol administration.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

Figure: see text

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Ayub-Ferreira et al. (Tue,) reported a other. Carvedilol was evaluated for the prevention of chemotherapy-induced cardiotoxicity, though specific clinical outcomes are not provided in the abstract.

synapsesocial.com/papers/6a025ca2edf6f4813859481f https://doi.org/https://doi.org/10.1016/j.jaccao.2025.12.009

Bookmark

View Full Paper